Monitor vesting dates—particularly November 20, 2026—for potential insider selling or exercise activity. Given the low exercise price relative to potential future valuation, this could become relevant in later-stage financing or exit scenarios.
Price Chart
Executive Summary
Rubin Eyal, CFO and EVP of Nasus Pharma Ltd, filed a Form 3 disclosing ownership of unvested stock options for 126,197 ordinary shares. The options were granted on November 20, 2025, with an exercise price of $7.56 per share and expire on November 20, 2035. No shares were acquired or sold in this filing; it is a mandatory initial ownership report.
Key Facts
- Form 3 filed by Rubin Eyal, CFO and EVP of Nasus Pharma Ltd, on March 27, 2026, reporting initial beneficial ownership.
- Two option grants disclosed: 85,648 options vesting starting February 27, 2027, and 40,549 options vesting fully on November 20, 2026.
- Total options: 126,197 ordinary shares at $7.56 exercise price, expiring November 20, 2035.
- As of March 18, 2026, none of the options are vested.
- No actual shares were bought or sold; this is a routine regulatory filing for initial ownership disclosure.
Financial Impact
No immediate financial impact. Potential future dilution of approximately 126,197 shares if fully exercised, representing about 0.48% of current market cap assuming $7.56 exercise price and $26M market cap.
Risk Factors
- Future share dilution if options are exercised.
- Potential insider selling pressure upon vesting, especially given the lack of current equity ownership disclosure.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001493152-26-013399 |
| Document: 0001493152-26-013399-index.html | 0001493152-26-013399 |
| Document: 0001493152-26-013399.txt | 0001493152-26-013399 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 18d ago | 6-K | $3.51 | awaiting T+20 | — | $3.49 (−0.57%) |
Sep 23, 2026 4w ago | 3 | $3.64 $3.06 | ▼ −15.93% | ▼ −16.62% | $3.49 (−4.12%) |
Sep 18, 2026 5w ago | 424B5 | $3.44 $3.21 | ▲ +6.83% | ▲ +5.92% | $3.49 (−1.45%) |
Sep 14, 2026 6w ago | 6-K | $3.65 $3.32 | ▼ −9.04% | ▼ −11.30% | $3.49 (−4.38%) |
Sep 14, 2026 6w ago | EFFECT | $3.65 $3.32 | ▼ −9.04% | ▼ −11.30% | $3.49 (−4.38%) |
Aug 21, 2026 9w ago | EFFECT | $4.00 $3.44 | ▼ −14.00% | ▼ −13.47% | $3.49 (−12.75%) |
Aug 19, 2026 9w ago | 6-K | $3.84 $3.53 | ▼ −8.07% | ▼ −6.12% | $3.49 (−9.11%) |
Aug 17, 2026 10w ago | 6-K | $3.70 $3.59 | ▼ −2.97% | ▼ −1.00% | $3.49 (−5.68%) |
Aug 17, 2026 10w ago | Press Release | $3.70 $3.59 | ▼ −2.97% | ▼ −1.00% | $3.49 (−5.68%) |
Apr 1, 2026 29w ago | EFFECT | $2.55 $2.56 | ▼ −0.39% | ▲ +9.33% | $3.49 (−36.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers